Ann: Breakthrough Zantrene Heart Protection Discovery, page-303

No problem.

Also, you may want to gloss over the data below, as it is what Daniel was referring to regarding the potential for heart muscle cell growth. The table below is taken from a clinical trial investigating Zantrene in refractory lymphoma (1). This particular table is showing the cardiac ejection fraction before and after 5 or more courses of Zantrene with prior doxorubicin treatment listed for each patient. Of particular interest is the improvement in cardiac ejection fraction in the patient that had no prior doxorubicin treatment and received 7080 mg/m2 cumulative dose of Zantrene.



The major limitations with interpreting the data like this is the small dataset and inconsistencies with measuring cardiac ejection fraction. However, I thought it was interesting to see this data when you graphed it (below).

There are the four key points that you can draw out from this data:
1. As the dose of prior doxorubicin treatment increased, cardiac ejection fraction difference got worse (left); and
2. As the dose of bisantrene treatment increased, cardiac ejection fraction difference improved (right); and


3. As the dose of prior doxorubicin treatment increased, after bisantrene cardiac ejection fraction decreased (left); and
4. As the dose of Bisantrene treatment increased, after bisantrene cardiac ejection fraction increased (right).


Obviously, this is a super small sample size and would need many more numbers before this data set could be used to draw strong inferences, however, it is very interesting to look at. In truth, I don't know whether Zantrene will be regenerative, and I am not holding onto that notion much at all, as we don't need it to be for RAC to have success in improving the efficacy and safety profile of anthracyclines or other cardiotoxic agents. I think it is fair to say, though, that this data gives an indication that Zantrene is not behaving like a regular anthracycline, and may reflect aspects of the discovery last week quite well.

Hopefully the phase 2b can begin to answer some of our questions, @bourse.

1 https://pubmed.ncbi.nlm.nih.gov/3581102/